An airless dispenser is a vacuum-pump pack: instead of dipping into a jar or pulling product through a straw, each press lifts an internal platform and pushes the cream out while no air re-enters the container. That sealed, one-way flow prevents oxygen and microbes from getting back into the formula, which is why it’s more hygienic and why sensitive actives hold their potency for longer. You also get metered dosing, minimal hand contact, and far less evaporation, so the texture, pH and fragrance remain stable throughout the product’s life. For clinics, this means better back-bar hygiene, fewer preservatives needed, near-total product evacuation (little waste), and improved quality assurance—every pump delivers a consistent dose that hasn’t been repeatedly exposed to fingers or room air.
Operationally: prime the pump on first use, wipe the nozzle after dispensing, don’t open the pack to “scoop the last bit” (it breaks the vacuum), store away from heat and direct light, and record the open date. A simple client script is: “It’s not a jar because jars let in air and fingers. This vacuum pump keeps the cream sealed, fresh and clean, and gives you the same measured dose every
Dermaceutic Hyal Ceutic Redens+ is a barrier-repair, high-hydration moisturiser designed for mature, dehydrated and post-procedure skin. The formula combines multi-molecular-weight hyaluronic acid (to hydrate across layers), polyglutamic acid from natto (to lock in moisture and reduce enzymatic breakdown of the matrix), and a lipid phase rich in ceramides with shea and jojoba to rebuild the skin’s barrier. It is delivered in a lamellar emulsion—organised in skin-like bilayers—for superior comfort without greasiness, and housed in an airless pump to protect actives and maintain back-bar hygiene. The brand positions the product as “redensifying” and contour-supportive; treat these as cosmetic claims that relate to improvements in hydration, elasticity and surface smoothness rather than structural remodelling.
The science is straightforward and defensible for clinic use. High-molecular-weight hyaluronic acid forms a breathable film that reduces transepidermal water loss and provides immediate comfort. Mid-weight fractions hydrate through the superficial epidermis and the dermo-epidermal junction, supporting elasticity perception. Lower-weight fragments can signal via receptors such as CD44 to promote repair, improving tolerance to actives. Polyglutamic acid is a water-binding biopolymer with very high humectancy; preclinical data suggest it inhibits hyaluronidase and may moderate other matrix-degrading enzymes, which helps hydration persist for longer. The ceramide-dominant lipid phase, supported by shea and jojoba, replaces depleted barrier lipids and improves resilience. The net clinical effect your team can stand over is better hydration, reduced tightness and stinging, and improved tolerance to corrective programs.
Evidence should be communicated with integrity. Brand in-vivo data (small cohort, 56 days) report increases in perceived firmness and density with reduced cheek ptosis and high user satisfaction. Present these as brand-run outcomes rather than peer-reviewed endpoints. Independent literature, however, robustly supports the mechanisms used here: multi-weight hyaluronic acid improves hydration and transepidermal water loss; ceramide-rich creams restore barrier function; polyglutamic acid shows high water-binding capacity and hyaluronidase inhibition in preclinical work. Your safe, compliant message to clients is that Redens+ delivers sustained hydration and barrier repair, which in turn optimises comfort and the visible performance of other actives.
Selection is simple. Choose Redens+ for mature, dry, or dehydrated skin; menopausal dryness; barrier-impaired presentations; and post-procedure care once the epidermis is intact. It is also useful when building tolerance to retinoids or acids. Very oily or breakout-prone clients may prefer a lighter daytime option; assess tolerability with a sample or limit Redens+ to evening use. The formula contains soy-derived ingredients—Glycine Soja (soybean) oil and potassium hydrolysed poly-γ-glutamate (natto gum)—so clients with a confirmed IgE-mediated soy allergy should be offered a soy-free alternative. For unclear histories or non-IgE sensitivities, carry out and document a 48–72-hour patch test. In pregnancy or breastfeeding, the moisturiser is generally suitable as a hydrating barrier product; continue to patch test in very reactive skin and avoid applying to broken skin.
Application should be operationalised for consistency. In the morning, cleanse, apply any antioxidant serum, then Redens+ sparingly, followed by broad-spectrum SPF 50. In the evening, cleanse, apply corrective serum or retinoid, and finish with Redens+. For clients starting retinoids, micro-dose by mixing a pea of retinol with a pea of Redens+ for the first one to two weeks, then separate and increase frequency as tolerated. Typical dosing is half to two-thirds of a millilitre for the face and slightly less for the neck. Advise clients not to layer multiple occlusives on top; by day, SPF sits over Redens+, and by night, Redens+ generally completes the routine.
Integration with treatment pathways is where Redens+ adds business value. After non-ablative procedures—chemical peels, RF, IPL, microneedling once re-epithelialised—it improves comfort, reduces visible flaking and supports adherence. Within pigmentation protocols, it stabilises the barrier while targeted agents such as tranexamic acid blends, azelaic acid, or retinoids do the corrective work. During retinoid ramps, nightly Redens+ from day one reduces drop-off and supports progression to effective frequencies. Pairing with LED can further modulate inflammation in sensitive clients.
Risk management and governance remain key. Record the soy-derived allergen status on the client file whenever Redens+ is used or dispensed. Where indicated, perform a patch test behind the ear or on the inner forearm and document site, timing, and read-out at 48–72 hours. Introduce only after re-epithelialisation post-treatment and avoid application to abraded areas. Store capped, note the open date on back-bar stock, and keep away from heat.
Troubleshooting is predictable. If a client reports heaviness, reduce the dose, restrict use to night-time, or apply only to dryness-prone zones; alternatively, switch to a lighter daytime hydrator such as Hydrating B5 and reserve Redens+ for evening. If tightness persists by afternoon, increase the evening amount or layer a humectant serum underneath; review water intake and ambient humidity. If breakouts occur, confirm dosing, avoid the T-zone, and consider alternating with a lighter moisturiser. For confirmed soy allergy, pivot to a verified soy-free alternative such as Triple Lipid 2:4:2 or Hydrating B5, checking INCI lists per batch.
In summary, Dermaceutic Hyal Ceutic Redens+ is best positioned in your protocols as a high-comfort hydration and barrier-repair workhorse that enhances client tolerance and elevates outcomes across correction and maintenance. Keep claims grounded in what the evidence supports—hydration, TEWL reduction and comfort—while using clear documentation and allergen controls to maintain clinical governance.
